WEBVTT

NOTE
This file was generated by Descript 

00:00:01.501 --> 00:00:03.019
Welcome to Oxford+.

00:00:03.022 --> 00:00:06.661
The podcast series for innovators
and investors brought to you in

00:00:06.661 --> 00:00:08.305
partnership with Mishcon de Reya.

00:00:08.560 --> 00:00:12.610
Our guest today is Camilla Easter,
CEO of Oxford Medical Products.

00:00:13.000 --> 00:00:16.800
Camilla started her career as a vet
before pivoting into the world of

00:00:16.800 --> 00:00:20.880
startups where she sought the opportunity
to make a real impact on the world.

00:00:21.157 --> 00:00:24.432
After five years fast-paced
work, culminating in a role as

00:00:24.432 --> 00:00:29.142
COO, Camilla took on the role at
Oxford Medical Products in 2019.

00:00:29.397 --> 00:00:34.346
Now on the back of clinical trial results
and an IDE approval to start a large scale

00:00:34.346 --> 00:00:38.966
trial in the US, that dream of impacting
billions of lives is closer than ever.

00:00:39.356 --> 00:00:44.136
With their obesity fighting pills, Sirona
being offered as an alternative to GLP-1

00:00:44.156 --> 00:00:46.727
therapies such as Ozempic and Mounjaro.

00:00:47.006 --> 00:00:50.906
They are poised to deliver results to
those who can't use existing therapies

00:00:51.206 --> 00:00:52.796
or who want to be weaned off them.

00:00:53.147 --> 00:00:55.307
Camilla, thank you so
much for joining today.

00:00:55.701 --> 00:01:01.191
I want to start off by getting a bit of
context for Oxford Medical Products, what

00:01:01.191 --> 00:01:02.811
you're doing, what stage you're up to.

00:01:03.081 --> 00:01:04.851
Super, and thank you for having me.

00:01:05.669 --> 00:01:09.149
I guess a little bit of a background
on Oxford Medical Products, OMP.

00:01:09.719 --> 00:01:14.284
We are a totally different
solution for obesity, and for

00:01:14.284 --> 00:01:16.474
weight management more in general.

00:01:17.024 --> 00:01:19.641
When we look at this market I think it's
useful to take a step back and understand

00:01:19.641 --> 00:01:22.311
the problem, and then I can tell you
a little bit more about the solution.

00:01:22.801 --> 00:01:28.111
Currently we have over 2 billion people
worldwide living with overweight or

00:01:28.111 --> 00:01:31.583
obesity and when we look at places
like the US and Europe, that's

00:01:31.583 --> 00:01:34.703
sort of 60, 70% of our population.

00:01:35.193 --> 00:01:39.238
At OMP, we took a step back and we
said, well, when we have a disease

00:01:39.238 --> 00:01:42.732
that's affecting so many people,
with so many different demographics

00:01:42.732 --> 00:01:46.992
and backgrounds, it's a very complex
disease, we need multiple solutions.

00:01:47.295 --> 00:01:50.662
We could see these incretin hormone
therapies coming through, and we

00:01:50.662 --> 00:01:52.252
said, let's do something different.

00:01:52.252 --> 00:01:57.532
Let's go back to basics and let's
create a non-pharmacological treatment

00:01:57.532 --> 00:01:59.092
for obesity, which is what we've done.

00:01:59.962 --> 00:02:00.622
Amazing.

00:02:00.932 --> 00:02:03.635
Why don't you explain a little bit
about the actual technology you have

00:02:03.635 --> 00:02:07.972
designed, but also if you wouldn't
mind, how you designed what you wanted

00:02:07.972 --> 00:02:12.322
to produce, because it's a little bit
atypical for things coming out of Oxford.

00:02:12.732 --> 00:02:17.828
Absolutely, so when we looked at this
problem, we said, well, what else works?

00:02:17.828 --> 00:02:20.048
You know, how else have
people been treating obesity?

00:02:20.048 --> 00:02:23.768
And of course the obvious solution is
diet and exercise, and we can go into

00:02:23.768 --> 00:02:27.758
the complexities around that and why
that doesn't work on a society scale.

00:02:28.238 --> 00:02:30.128
But also bariatric surgery.

00:02:30.178 --> 00:02:34.708
Bariatric surgery works incredibly
well on an individual basis.

00:02:34.838 --> 00:02:37.863
But when we look at the
world's population, we cannot

00:02:37.863 --> 00:02:39.333
operate on 2 billion people.

00:02:39.363 --> 00:02:40.683
We don't have the resources.

00:02:40.833 --> 00:02:44.823
It's far too expensive, and to be
honest, it's just too invasive as well.

00:02:45.247 --> 00:02:48.787
But at its most fundamental,
essentially what bariatric surgery

00:02:48.787 --> 00:02:51.547
is doing is it's reducing the
available volume in your stomach.

00:02:51.937 --> 00:02:55.807
So we said there must be a less
invasive way to do this, and so

00:02:55.897 --> 00:02:59.887
between our founding team, we have
come up with our technology Sirona.

00:03:00.427 --> 00:03:02.887
So Sirona is a dual polymer hydrogel.

00:03:02.962 --> 00:03:06.322
Which means it has ability to
absorb water very, very rapidly

00:03:06.322 --> 00:03:08.392
and expand multiple times its size.

00:03:08.842 --> 00:03:11.812
So essentially what this means is
we've created a pill, you can just

00:03:11.812 --> 00:03:15.082
take it home, comes in a blister pack,
looks like a paracetamol, and when you

00:03:15.082 --> 00:03:18.352
swallow it with a glass of water, it
expands really rapidly in the stomach

00:03:18.352 --> 00:03:22.016
to about the size of a golf ball, and
there it stays for several days before

00:03:22.016 --> 00:03:24.326
it breaks down and passes naturally.

00:03:24.893 --> 00:03:28.223
What this means is by taking one or
two of these pills a day, you reduce

00:03:28.223 --> 00:03:29.663
the available volume of your stomach.

00:03:29.903 --> 00:03:32.393
You reduce the amount of food
that you will want to eat, and

00:03:32.393 --> 00:03:35.663
ultimately, of course, that leads to
a calorie deficit and weight loss.

00:03:35.963 --> 00:03:39.773
But in a much more manageable way
for the individual taking away those

00:03:39.773 --> 00:03:43.593
desires to eat and that urge and that
hunger that we have when we're dieting.

00:03:44.173 --> 00:03:47.149
In terms of how we got set up,
it was very unusual, as you say.

00:03:47.149 --> 00:03:50.963
So, I personally had worked another
university spinout several years ago.

00:03:51.415 --> 00:03:55.795
Chairman Nick Edwards, again, very
involved with the ecosystem, and when

00:03:55.795 --> 00:04:01.225
we came up with this concept back
in 2016, it was at a time when the

00:04:01.225 --> 00:04:04.075
university structure of spinouts was
very different to what it is today,

00:04:04.075 --> 00:04:07.615
and I'd like to sort of say that, but
the university we're taking quite a lot

00:04:07.675 --> 00:04:11.030
of the percentages of these spin outs
of companies and just wasn't something

00:04:11.030 --> 00:04:12.350
that we wanted to do at this point.

00:04:12.350 --> 00:04:15.770
We'd come up with this idea
completely outside of the university.

00:04:16.010 --> 00:04:19.310
All of our founders were outside of the
university and so we said, well, let's

00:04:19.310 --> 00:04:20.880
not go and spin out of the university.

00:04:20.900 --> 00:04:24.080
Let's go and see who their best material
scientists are cause of course they do

00:04:24.080 --> 00:04:26.520
have phenomenal talent at the university.

00:04:26.580 --> 00:04:31.000
So, Dr Xue Min, who is our CSO,
she was just finishing up her

00:04:31.000 --> 00:04:34.160
DPhil there in biomaterials and
we took her out of the university.

00:04:34.160 --> 00:04:37.220
We employed her directly and
she essentially did a postdoc,

00:04:37.220 --> 00:04:39.230
but within the company itself.

00:04:39.290 --> 00:04:42.410
So by the end of, I think it was like
two and a half years of iteration after

00:04:42.410 --> 00:04:47.480
iteration of different materials, she came
up with what was to go on to become Sirona

00:04:47.540 --> 00:04:51.290
and that's when we really put the core
team together, and got going from there.

00:04:51.820 --> 00:04:55.460
Because you have a different
equity shareholder base, because

00:04:55.460 --> 00:04:58.580
you're not a university spinout,
how do you think this has impacted

00:04:58.580 --> 00:05:00.110
the shape of your investor base?

00:05:00.210 --> 00:05:02.850
Both positives and perhaps
any negatives that you observe

00:05:02.850 --> 00:05:03.960
now with a bit of hindsight?

00:05:04.730 --> 00:05:08.230
When we got going, rather than
having OSE on board in terms of that

00:05:08.320 --> 00:05:11.316
big fund behind you, which a lot
of university spin outs will have.

00:05:11.616 --> 00:05:13.986
We did a much more, I guess,
historically traditional route.

00:05:14.006 --> 00:05:17.726
So we went to high net worth
individuals around the Oxford ecosystem

00:05:18.086 --> 00:05:19.496
and did our pre-seed like that.

00:05:19.496 --> 00:05:23.456
So it was just funded by high net worth
individuals who maybe had founded their

00:05:23.456 --> 00:05:27.166
own companies here, et cetera, and then
of course, as we, became bigger and

00:05:27.166 --> 00:05:30.916
we had to raise more money, we just
went to London, to Cambridge and the

00:05:30.916 --> 00:05:34.806
rest of Europe ultimately and put our
seed together with some sort of sector

00:05:34.806 --> 00:05:37.616
agnostic that sort of seed VC funds.

00:05:37.695 --> 00:05:40.545
And what that meant was it was
a slightly different route.

00:05:40.545 --> 00:05:45.765
We didn't necessarily go down the pure
biotech route that we may well have done,

00:05:45.765 --> 00:05:50.434
I think if we had been more closely sort
of related to the university and to OSE

00:05:50.434 --> 00:05:56.358
at the time, and so it did give us this
broader shareholder base and interestingly

00:05:56.390 --> 00:06:00.230
I think if you'd asked me that question
12 months ago, I would've said, I

00:06:00.230 --> 00:06:01.640
think that was quite a detriment to us.

00:06:01.640 --> 00:06:06.330
I think we needed that more sort of
scientific, biotech base, but actually,

00:06:06.380 --> 00:06:11.750
today what we've seen with obesity as a
disease and the way it is being treated

00:06:11.825 --> 00:06:13.985
it's a much more consumer approach.

00:06:14.495 --> 00:06:19.185
So when you look at individuals,
buying  Mounjaro, sort of Zepbound

00:06:19.205 --> 00:06:22.620
or Wegovy, which are the two drugs
from Lilly and Novo for obesity.

00:06:23.100 --> 00:06:27.750
95% of people in the UK buying those
drugs are buying them out of pocket.

00:06:28.110 --> 00:06:30.750
They're going on telemedicine and
they're paying for them themselves.

00:06:30.930 --> 00:06:33.510
This is not being
reimbursed through the NHS.

00:06:33.510 --> 00:06:36.720
This is not being reimbursed through
any healthcare system really in Europe.

00:06:36.720 --> 00:06:40.305
Not across a scale that it ultimately
needs to be, or in fact is being used.

00:06:40.558 --> 00:06:44.520
Now we have this different small
sector agnostic shareholder base,

00:06:44.520 --> 00:06:48.750
which is really coming into its own
as this becomes more of a consumer

00:06:48.750 --> 00:06:53.015
driven treatment option rather than
your traditional pharma biotech.

00:06:53.750 --> 00:06:56.940
You and I have spoken about funding in
the current macroeconomic environment,

00:06:56.970 --> 00:07:00.270
which for anyone listening when
we record this, we are right in

00:07:00.270 --> 00:07:01.830
the middle of the Trump tariffs.

00:07:01.830 --> 00:07:06.180
In fact, yesterday he announced for
context the tariffs on the film industry.

00:07:06.180 --> 00:07:08.725
So that will tell anyone listening
where we are in the playbook,

00:07:08.725 --> 00:07:10.120
where in sort of early May.

00:07:11.117 --> 00:07:14.807
It's a nightmare for a company,
any company, raising money.

00:07:15.437 --> 00:07:19.397
How are you seeing that your
investor base is responding to that?

00:07:19.457 --> 00:07:22.867
What are concerns that you have
and where are you at with that?

00:07:23.427 --> 00:07:27.627
So we finished our most recent trial,
really towards the backend of last year.

00:07:27.627 --> 00:07:31.137
So we started gearing up for our Series
A towards the backend of last year.

00:07:31.172 --> 00:07:33.105
and we were getting some
lovely meetings in the diary.

00:07:33.105 --> 00:07:37.535
We were starting to make fantastic
relationships, and interestingly as the

00:07:37.535 --> 00:07:42.715
tarrifs really truly hit, I think everyone
took a sort of sharp breath in and I

00:07:42.715 --> 00:07:44.005
would say everything just slowed down.

00:07:44.005 --> 00:07:48.445
It wasn't so much that the whole
landscape disappeared, but you know,

00:07:48.445 --> 00:07:50.455
meetings took longer to get in the diary.

00:07:50.725 --> 00:07:54.715
Everything just seems much slower at the
moment, and that's true, you know, we

00:07:54.715 --> 00:07:58.495
are speaking both to VCs, but we're also
speaking a lot to strategics at the moment

00:07:58.785 --> 00:08:02.865
and of course those strategics are being
incredibly affected and they have to work

00:08:02.865 --> 00:08:04.245
out, you know, where do we manufacture?

00:08:04.285 --> 00:08:06.745
What's the influence
of these tariffs on us?

00:08:06.775 --> 00:08:11.125
And so everything has really slowed
down and we can see that across the

00:08:11.125 --> 00:08:12.925
board in terms of deals being done.

00:08:13.495 --> 00:08:19.765
We've got to, as a sector,
really just ensure that we have

00:08:19.975 --> 00:08:22.033
runway to weather this period.

00:08:22.083 --> 00:08:23.043
It will be fine.

00:08:23.386 --> 00:08:24.736
Things will pick up.

00:08:24.826 --> 00:08:27.918
But ultimately we have to
survive this slower period.

00:08:27.998 --> 00:08:33.058
So at OMP, we have been making sure
that we can deliver on milestones that

00:08:33.058 --> 00:08:34.618
we can do within our current budget.

00:08:34.618 --> 00:08:38.698
So for instance, and we just put in our
IDE, so this is the approval that we

00:08:38.698 --> 00:08:43.148
need in order to conduct our big pivotal
trials to get market approval for Sirona,

00:08:43.198 --> 00:08:46.318
and that's something we were able to run
internally ourselves with the team that we

00:08:46.318 --> 00:08:50.098
have, and we flew through that process and
I was also conscious of what's going on at

00:08:50.098 --> 00:08:55.243
the FDA said, right, we have to execute on
this now before more changes at the FDA.

00:08:55.333 --> 00:08:56.713
We can already see the rapid changes.

00:08:56.713 --> 00:09:01.243
So I think just being adaptive
where you can to the current

00:09:01.513 --> 00:09:03.783
climate is all you can do as a CEO.

00:09:04.143 --> 00:09:08.803
Yeah, and it's an interesting one because
I think for some companies that are so US

00:09:08.803 --> 00:09:11.188
focused in terms of their domestic market.

00:09:11.996 --> 00:09:16.136
It's going to be very unsettling, but you
have a product that affects so many people

00:09:16.376 --> 00:09:21.446
or that would be beneficial to so many
that hopefully you can pivot and refocus.

00:09:21.562 --> 00:09:23.422
It's an extraordinary
market that you are in.

00:09:23.512 --> 00:09:26.212
It does have this global application.

00:09:26.392 --> 00:09:30.832
How are you narrowing down where you are
focusing and how do you see that puzzle?

00:09:31.111 --> 00:09:34.411
So as I said, we've approached this
disease very, very differently.

00:09:34.411 --> 00:09:38.476
We've got Lilly and Novo dominating
this field with their incretin hormone

00:09:38.476 --> 00:09:40.306
therapies, which are very effective.

00:09:40.306 --> 00:09:41.596
There's no question about it.

00:09:42.166 --> 00:09:45.376
But when we have a disease that
is affecting more than 2 billion

00:09:45.376 --> 00:09:47.296
people, we need these multiple tools.

00:09:47.926 --> 00:09:51.556
And so from the recent data from a
study we've just done across actually

00:09:51.556 --> 00:09:55.696
three NHS hospitals, we were able to
see that our products working incredibly

00:09:55.696 --> 00:10:00.136
well, but particularly in individuals
who have a lower class of obesity.

00:10:00.196 --> 00:10:03.823
So we looked at people with a BMI
of 30 to 40, and we found that

00:10:03.823 --> 00:10:08.083
people with a BMI of 30 to 35, which
is class one obesity, responded

00:10:08.083 --> 00:10:09.463
incredibly well to the treatment.

00:10:09.973 --> 00:10:13.603
And then in sort of further discussions
with the FDA, going through this IDE

00:10:13.633 --> 00:10:17.563
process, we have actually decided,
in our pivotal trials, to look at

00:10:17.563 --> 00:10:21.913
everybody with overweight and class
one and class two obesity and that's

00:10:21.913 --> 00:10:23.853
because of our risk benefit profile.

00:10:23.853 --> 00:10:27.683
So we saw phenomenal side effect
profile we saw sort of very little,

00:10:27.683 --> 00:10:30.953
almost no vomiting and diarrhea
and constipation, which means we

00:10:30.953 --> 00:10:33.983
could be very, very suitable for
people living with overweight.

00:10:34.073 --> 00:10:38.093
Whereas these GLP-1s are licensed
for people with BMI of 30 and

00:10:38.093 --> 00:10:40.043
over, or 27 with comorbidity.

00:10:40.343 --> 00:10:43.883
So really trying to be sort of preemptive
in our treatment approach there.

00:10:44.443 --> 00:10:48.033
Secondly, the other area that we
think we have huge potential in is

00:10:48.033 --> 00:10:49.953
in the weight maintenance space.

00:10:50.343 --> 00:10:54.403
So what do we do with these millions
and millions of people taking GLP-1?

00:10:54.423 --> 00:10:57.453
They're working incredibly well
to reduce their weight, but we

00:10:57.453 --> 00:11:01.803
also know that 70% of people stop
taking these drugs within a year.

00:11:02.283 --> 00:11:05.283
And further to that, we also
know that 70% of the weight

00:11:05.358 --> 00:11:07.288
comes back on within 12 months.

00:11:07.588 --> 00:11:10.168
So we must find a way to keep
that weight off long term.

00:11:10.228 --> 00:11:14.668
The weight is lost as fat and as
muscle, and we don't really want to

00:11:14.668 --> 00:11:18.358
be losing muscle, particularly as
we get older, and unfortunately when

00:11:18.358 --> 00:11:22.108
that weight starts to come back on, it
is nearly all coming back on as fat.

00:11:22.108 --> 00:11:25.523
So these individuals end up in a worse
metabolic state than they were before.

00:11:25.943 --> 00:11:30.088
So we believe that Sirona could be an
absolutely fantastic option long term.

00:11:30.088 --> 00:11:33.518
So you take your GLP-1 if that's
appropriate for you at that stage.

00:11:33.649 --> 00:11:36.169
You lose that weight and then
you transition onto Sirona for

00:11:36.169 --> 00:11:38.629
long-term weight maintenance.

00:11:38.989 --> 00:11:43.519
Because of our safety profile, because of
our cogs, we're very, very well positioned

00:11:43.519 --> 00:11:45.019
for long-term weight management.

00:11:45.295 --> 00:11:47.035
That makes so much sense and particularly.

00:11:47.620 --> 00:11:50.500
You know, another thing you haven't even
touched upon, especially there, but we

00:11:50.500 --> 00:11:53.950
all know, is these things are expensive,
and I was incredibly struck by what you

00:11:53.950 --> 00:11:58.240
said earlier in the conversation, that
95% of people are paying out of pocket.

00:11:58.570 --> 00:12:02.650
So that's a huge contributing factor as
well, that they're just too expensive

00:12:02.650 --> 00:12:04.930
for people to fund themselves long term.

00:12:05.350 --> 00:12:08.965
Also, when I was looking through your
deck, which is just so excellent and full

00:12:08.965 --> 00:12:13.435
of slightly terrifying statistics, if I'm
honest, about the unknown consequences

00:12:13.435 --> 00:12:17.725
of some of these drugs long term,
like osteoporosis being another one

00:12:17.725 --> 00:12:19.645
in terms of stripping out, nutrients.

00:12:20.035 --> 00:12:24.205
But in that cohort you've identified
there where the BMI is 25 to 30,

00:12:24.355 --> 00:12:28.135
the mortality rates from that
overweight, but not being technically

00:12:28.135 --> 00:12:29.995
obese, are still exceptionally high.

00:12:30.735 --> 00:12:31.360
That's right.

00:12:31.360 --> 00:12:34.540
So there was this great paper published
in the New England Journal, which

00:12:34.540 --> 00:12:39.063
essentially said, it's not just about
disease happening when you become obese,

00:12:39.303 --> 00:12:43.443
actually this is a chronic disease and
it's progressive, and so as soon as

00:12:43.443 --> 00:12:46.653
you start to carry excessive weight,
an excessive weight for you will be

00:12:46.653 --> 00:12:49.806
very different from excessive weight
to me, and we use BMI because it's

00:12:49.806 --> 00:12:51.846
a very useful tool on a large scale.

00:12:52.506 --> 00:12:56.016
But absolutely as soon as we start
to carry extra adipose tissue,

00:12:56.016 --> 00:12:58.986
which is the cell that stores
the fat in it, we start to have

00:12:58.986 --> 00:13:00.516
increased inflammation in our body.

00:13:00.696 --> 00:13:03.816
Chronic inflammation is a
terrible thing for aging, for

00:13:03.816 --> 00:13:05.886
cancers, for osteoarthritis.

00:13:06.016 --> 00:13:11.056
So many chronic disease can be found in
that root cause of chronic inflammation.

00:13:11.106 --> 00:13:15.506
Any way that we can stop that in a safe
manner is going to be advantageous for

00:13:15.506 --> 00:13:17.516
individuals and society as a whole.

00:13:18.201 --> 00:13:21.829
Slightly off the main subject I appreciate
here, but given that there is this trend.

00:13:21.830 --> 00:13:24.410
We've almost got these two
extremes in society at the moment.

00:13:24.410 --> 00:13:27.550
You've got people dealing with obesity
and overweight and then you've got

00:13:27.550 --> 00:13:30.427
people trying to live forever that
we're reading about and fight aging.

00:13:30.782 --> 00:13:35.009
Do you think as a professional in
this field that we all will be taking

00:13:35.009 --> 00:13:38.849
something like this in 10 years
time to try and lower inflammation?

00:13:39.914 --> 00:13:41.114
Ooh, that's a great question.

00:13:41.204 --> 00:13:44.984
So I think longevity's very
complex when we look at that as

00:13:44.984 --> 00:13:47.014
a sort of sub-sector of biotech.

00:13:47.614 --> 00:13:51.744
I don't know the answer to everybody,
but when we have this disease, obesity,

00:13:51.744 --> 00:13:56.334
and excessive weight that's affecting
70% of our population, arguably this

00:13:56.334 --> 00:13:58.254
should be being used on a society scale.

00:13:58.254 --> 00:14:03.111
I did a talk a few weeks ago now and
there was a pharma leader there on the

00:14:03.111 --> 00:14:07.311
panel and I was getting a lot of feedback
from the audience that we shouldn't

00:14:07.311 --> 00:14:10.521
be treating obesity as a disease, we
should be going diet and exercise.

00:14:10.791 --> 00:14:15.391
And it got animated, shall we say, and
the pharma guy that was next to me who his

00:14:15.391 --> 00:14:18.751
pharma company, doesn't have an obesity
asset, just turned around and said, I

00:14:18.751 --> 00:14:20.641
think we should put GLP-1s in the water.

00:14:20.936 --> 00:14:22.466
That is the scale of this problem.

00:14:22.512 --> 00:14:24.432
Now, I'm not saying that that's
where we're at, but I could

00:14:24.432 --> 00:14:25.902
see he was being provocative.

00:14:25.902 --> 00:14:28.422
But I can see his point
of where he's coming from.

00:14:28.932 --> 00:14:34.492
If we can reduce the burden of obesity
and excessive weight on individuals and

00:14:34.492 --> 00:14:38.062
on society the health economics are just
enormous and we can go into them, but

00:14:38.062 --> 00:14:39.742
they're just wild when you look at it.

00:14:39.742 --> 00:14:43.582
But the cost of these drugs is what's
preventing healthcare systems like

00:14:43.582 --> 00:14:45.172
the NHS, implementing them quicker.

00:14:45.202 --> 00:14:49.882
Cause it would cripple us if we were to
actually, as a society, treat everybody

00:14:49.882 --> 00:14:51.202
who was eligible for them at the moment.

00:14:51.202 --> 00:14:53.242
So we've had to come up with
different ways of doing it.

00:14:53.897 --> 00:14:56.567
I think that's fascinating cause it
sounds very extreme and to people

00:14:56.567 --> 00:14:59.867
listening who perhaps aren't in this
field, they would say, oh my God,

00:14:59.867 --> 00:15:00.797
you can't put things in the water.

00:15:01.007 --> 00:15:01.967
But it has been done.

00:15:02.244 --> 00:15:06.441
So fluoride being one example for teeth
and then iodine is one because when they

00:15:06.441 --> 00:15:09.831
worked out that people in the Midwest of
America were developing, what's it called?

00:15:09.831 --> 00:15:10.351
Goiter?

00:15:10.632 --> 00:15:13.272
But it was effectively because
they weren't getting any salt.

00:15:13.272 --> 00:15:14.654
And folic acid, of course, for women.

00:15:14.654 --> 00:15:15.083
Indeed.

00:15:15.083 --> 00:15:19.163
So it's not actually unprecedented
as much as it sounds quite extreme.

00:15:19.702 --> 00:15:20.092
Okay.

00:15:20.122 --> 00:15:22.552
Camilla, you're going to have to forgive
me, but when I've been reading all

00:15:22.552 --> 00:15:26.482
of this, and this is such a layperson
question, but I keep thinking, and I would

00:15:26.482 --> 00:15:29.572
like to know because I'm sure others may
think this when they hear the description.

00:15:29.752 --> 00:15:33.412
What would happen if I took four
of your pills and I was overdosed?

00:15:33.707 --> 00:15:36.017
No, that is an absolutely
fair question and what I get.

00:15:36.067 --> 00:15:37.447
From stupid people all the time?

00:15:37.492 --> 00:15:42.142
No, this isn't a stupid question because
we are treating a disease that is open

00:15:42.142 --> 00:15:45.722
to abuse, of course, and we need to make
sure that we're responsible with that.

00:15:46.382 --> 00:15:48.392
Of course, it's possible for
someone to try and take a whole

00:15:48.392 --> 00:15:49.982
packet or four of these at once.

00:15:50.403 --> 00:15:54.543
The short answer is you'll feel a little
bit sick, but nothing bad will happen.

00:15:54.543 --> 00:15:59.523
So there is no systemic absorption of the
hydrogel, what goes in ultimately comes

00:15:59.613 --> 00:16:04.593
out, and so you are not going to get
some horrible liver toxicity or kidney

00:16:04.593 --> 00:16:06.303
toxicity if you were to take too many.

00:16:06.663 --> 00:16:08.103
It would be a stupid mistake.

00:16:08.283 --> 00:16:09.693
You would feel a bit nauseous.

00:16:09.753 --> 00:16:13.328
But ultimately you'd be
absolutely fine long term.

00:16:13.848 --> 00:16:16.218
And we hear a lot more about gut biome.

00:16:16.218 --> 00:16:20.415
Clearly this has an interplay with
inflammatory markers that we see.

00:16:20.595 --> 00:16:22.035
It's not that well understood yet.

00:16:22.185 --> 00:16:24.855
Is it something that you are
studying and looking at and do

00:16:24.855 --> 00:16:28.185
you have any idea how your product
impacts factors like that yet?

00:16:28.675 --> 00:16:29.575
Yeah, absolutely.

00:16:29.575 --> 00:16:34.045
So we know that by reducing weight we
can really improve certain biomarkers.

00:16:34.045 --> 00:16:35.875
So glycemic control is an obvious one.

00:16:35.875 --> 00:16:39.805
I think we all understand with type two
diabetes, some liver enzymes as well.

00:16:39.805 --> 00:16:42.475
Some of our liver enzymes will start
to go up as our weight goes up cause

00:16:42.475 --> 00:16:46.165
we will store excess fat in our
liver and that's bad for our liver.

00:16:46.675 --> 00:16:50.295
So within our most recent study,
we were actually looking at

00:16:50.295 --> 00:16:53.665
individuals without type two diabetes
and things within this study.

00:16:53.665 --> 00:16:57.835
But we did have a subset of individuals
with pre-diabetes and we saw a shift

00:16:57.835 --> 00:16:59.635
change in their glycemic controls.

00:16:59.635 --> 00:17:03.295
So we looked at fasting glucose,
we looked at HbA1c for instance,

00:17:03.295 --> 00:17:05.695
and they were trending down across
all those individuals, which was

00:17:05.695 --> 00:17:07.045
a small portion of the study.

00:17:07.345 --> 00:17:10.615
So we'll continue to study that on
a much larger scale and in fact the

00:17:10.615 --> 00:17:14.735
study that we've just submitted to
FDA to carry out includes 25% of our

00:17:14.735 --> 00:17:19.325
population having pre-diabetes because
again, going back to who are we and

00:17:19.325 --> 00:17:20.825
where do we fit into this market?

00:17:21.455 --> 00:17:23.405
We are looking at sort
of preventative obesity.

00:17:23.585 --> 00:17:25.115
What about preventative diabetes?

00:17:25.355 --> 00:17:28.795
Why should we hit full blown type two
diabetes before we start to treat it?

00:17:28.825 --> 00:17:32.515
We can see it happening on the bloods,
and so we very much want to look at

00:17:32.515 --> 00:17:36.535
that can we actually stop individuals at
that pre-diabetic level and bring their

00:17:36.535 --> 00:17:38.920
glycemic control back under control.

00:17:39.310 --> 00:17:42.420
And as we know, these things are always
easier when they're not so far advanced.

00:17:42.420 --> 00:17:43.000
Absolutely.

00:17:43.255 --> 00:17:44.418
Really, really interesting.

00:17:44.598 --> 00:17:49.158
Thank you, that's been such a wonderful
understanding of what OMP is doing.

00:17:49.423 --> 00:17:52.903
I'm going to take a kind of different
pivot now, given that you are not a

00:17:52.903 --> 00:17:57.193
university spin out, it's even more of
an active choice to have started and

00:17:57.193 --> 00:18:01.653
stayed and be scaling your manufacturing
capabilities here in the region.

00:18:01.863 --> 00:18:05.313
Can you talk a bit more about why
you founded in Oxford, what the

00:18:05.313 --> 00:18:07.023
opportunities are here that you see?

00:18:07.483 --> 00:18:11.413
So although we're not a traditional spin
out, obviously from the university, that

00:18:11.438 --> 00:18:15.783
doesn't detract from the fact that Oxford
is an enormously amazing ecosystem.

00:18:16.023 --> 00:18:17.643
The talent that is around here.

00:18:17.673 --> 00:18:19.173
The capital that is also around here.

00:18:19.203 --> 00:18:22.083
Even outside of the university
and the attached funds there.

00:18:22.083 --> 00:18:24.783
There are still fantastic other
funds and high net worth individuals.

00:18:25.503 --> 00:18:28.713
And so it still makes sense to
be here and I think talent has

00:18:28.713 --> 00:18:30.483
to be one of the biggest drivers.

00:18:30.693 --> 00:18:33.823
So our CSO, we took her out of the
university, employed her directly.

00:18:34.213 --> 00:18:37.233
But her training and her
education is second to none

00:18:37.233 --> 00:18:38.703
having been at Oxford University.

00:18:38.973 --> 00:18:42.645
And then of course just within
that ecosystem we have quality

00:18:42.645 --> 00:18:43.935
and regulatory coming through.

00:18:43.935 --> 00:18:45.465
We have finance directors.

00:18:46.305 --> 00:18:49.935
All of that is because of this hub
that has essentially been set up around

00:18:49.935 --> 00:18:54.375
the university and those spin outs,
and so we can absolutely still benefit

00:18:54.495 --> 00:18:56.325
and utilize that infrastructure.

00:18:56.570 --> 00:18:59.750
You've illuminated some of the
really positive things there, but I

00:18:59.750 --> 00:19:02.510
know that when you were in Houston
recently, you were commenting on

00:19:02.510 --> 00:19:04.340
how great the environment was.

00:19:04.340 --> 00:19:08.750
So if you were to say, but I'd love to
see more of, what would those things be?

00:19:09.210 --> 00:19:09.870
Absolutely.

00:19:09.870 --> 00:19:12.810
So actually to be fair though, that was
through a BioBridge, which was through

00:19:12.810 --> 00:19:17.590
Innovate UK so still part of that UK
and EU ecosystem and so we spent about

00:19:17.590 --> 00:19:21.910
a month in the Texas Medical Center
in Houston last year and what struck

00:19:21.910 --> 00:19:26.610
me was the connectivity of the entire
place, and this is absolutely enormous.

00:19:26.610 --> 00:19:29.130
I can't remember how many hospitals,
but it's the biggest site in the

00:19:29.130 --> 00:19:32.310
world for number of hospitals and
number of doctors in one place.

00:19:32.610 --> 00:19:37.380
Every day, afternoon, evening, there would
be an event on just connecting people,

00:19:37.590 --> 00:19:40.725
and you could call up any individual
and say, I want to speak to so and so,

00:19:40.725 --> 00:19:41.925
and they would absolutely connect you.

00:19:41.925 --> 00:19:46.215
The infrastructure and the
sort of relationships around

00:19:46.215 --> 00:19:48.105
that were just so proactive.

00:19:48.105 --> 00:19:51.345
Everybody was just, let's get this
job done, even if it's not directly

00:19:51.345 --> 00:19:54.075
to me, I will connect you to that
right person because you are now

00:19:54.075 --> 00:19:57.345
part of our ecosystem and connecting
you will help the ecosystem.

00:19:57.345 --> 00:20:01.965
And it was just, that can do,
unbelievably positive mental

00:20:01.965 --> 00:20:04.125
attitude that I just loved.

00:20:04.125 --> 00:20:05.175
It was fantastic.

00:20:06.085 --> 00:20:08.075
I mean, that sounds to me like Americans.

00:20:08.255 --> 00:20:10.295
And that is one of the things, you
know when you get off the plane

00:20:10.295 --> 00:20:12.005
and it's like, welcome to Houston.

00:20:12.005 --> 00:20:13.775
You're like, why don't
we have that in the UK?

00:20:13.775 --> 00:20:16.535
Like let's talk about how
brilliant we are a little bit more.

00:20:16.535 --> 00:20:19.395
I think that's a very
helpful thing to have.

00:20:19.490 --> 00:20:23.320
So we've spoken more specifically
about some of the mini hubs and

00:20:23.320 --> 00:20:26.560
clusters in Oxford, and you have
subscribed towards one that's a

00:20:26.560 --> 00:20:28.900
coalescing of similar companies to you.

00:20:28.900 --> 00:20:32.460
Can you speak a little bit about where
you are and that mini cluster within

00:20:32.460 --> 00:20:34.230
the broader Oxfordshire cluster?

00:20:34.427 --> 00:20:36.887
I have a vested interest cause
I'm trying to grow this mini

00:20:36.887 --> 00:20:38.447
plastics, I think it's so fantastic.

00:20:39.107 --> 00:20:43.637
But essentially we had a base initially
on the Oxford Science Park which served us

00:20:43.637 --> 00:20:45.557
very, very well when we were very small.

00:20:45.800 --> 00:20:48.980
But we had to grow very rapidly,
which is a fantastic position to

00:20:48.980 --> 00:20:51.230
be in and we manufacture ourselves.

00:20:51.280 --> 00:20:55.540
So we went from needing a lab space
that was maybe a hundred foot square

00:20:55.540 --> 00:20:58.160
to needing 4,000 foot square of space.

00:20:58.700 --> 00:21:02.600
And of course, the cost of real estate, as
you know, in places at Central Oxford or

00:21:02.600 --> 00:21:07.347
even around in those hubs is astronomical,
and I have to then as CEO sit back

00:21:07.347 --> 00:21:09.717
and go, well, is that value for money?

00:21:09.807 --> 00:21:12.237
How is that creating more
value in the company?

00:21:12.657 --> 00:21:15.197
Well, the truth is actually there's
a balance to be had, isn't there?

00:21:15.647 --> 00:21:19.727
And I said, well, putting that money
into pure real estate is not creating

00:21:19.727 --> 00:21:21.287
value in the tech or in the people.

00:21:21.431 --> 00:21:24.814
So we started looking around and
actually we looked over in Witney.

00:21:25.214 --> 00:21:28.514
So we found a fantastic place, the
Wind rush Industrial Estate, they'd

00:21:28.514 --> 00:21:33.114
just built some empty industrial
units there and the cost of the real

00:21:33.114 --> 00:21:36.174
estate was much cheaper, but we still
had that infrastructure into Oxford.

00:21:36.834 --> 00:21:39.234
But actually when I started looking
further around, you know, we can see

00:21:39.234 --> 00:21:44.062
Abbott, from our windows, we've got, Owen
Mumford, Lombard, so the infrastructure

00:21:44.062 --> 00:21:47.242
from a MedTech point of view was
fantastic, and in fact, we've been

00:21:47.242 --> 00:21:52.282
able to recruit fantastic manufacturing
techs, quality, regulatory, all from

00:21:52.282 --> 00:21:56.872
around this environment that exists,
you know, 30 minutes west of Oxford

00:21:57.312 --> 00:22:02.562
and so I would encourage other founders
who need much more space to think about

00:22:02.562 --> 00:22:06.672
putting that infrastructure in themselves
and taking out industrial units.

00:22:06.852 --> 00:22:09.252
Particularly within, I would come and
have a look around Witney within that

00:22:09.252 --> 00:22:13.572
area because we were able to put in
class seven, class eight clean rooms.

00:22:13.572 --> 00:22:18.152
We're 13485 accredited and we've been
able to put all of the infrastructure in

00:22:18.152 --> 00:22:22.232
ourselves for still a fraction of the cost
that we would've lost just through rent.

00:22:22.237 --> 00:22:24.782
So I think it's just
looking at that solution.

00:22:24.782 --> 00:22:26.802
There are other ways,
to solve that problem.

00:22:27.297 --> 00:22:30.897
You spoke earlier about an event you were
at the other day and when you and I caught

00:22:30.897 --> 00:22:35.517
up, you went into even a bit more detail
about how surprised you were by some of

00:22:35.517 --> 00:22:40.287
the views of what was quite an educated
and healthcare focused audience that it

00:22:40.287 --> 00:22:46.347
was just healthcare, just healthy eating
and exercise in spite of some very poor

00:22:46.347 --> 00:22:48.147
results from policies focused on that.

00:22:48.507 --> 00:22:52.317
I'd love for the benefit of the listeners
to go into that in a bit more detail

00:22:52.317 --> 00:22:58.857
because it is still such a stigma and it's
really interesting how misplaced still

00:22:58.857 --> 00:23:00.627
some of our faith in those policies is.

00:23:01.482 --> 00:23:05.467
When I'm at an event like that and doing
a talk or something, I tend to ask the

00:23:05.467 --> 00:23:10.657
room really upfront, put your hand up
if you consider obesity to be a disease.

00:23:11.137 --> 00:23:14.587
And for me that's a really good
marker of where the audience is at.

00:23:15.105 --> 00:23:18.315
So I spent a lot of time in the US last
year and actually the beginning of this

00:23:18.315 --> 00:23:23.355
year, and you would see sort of plus
80, normally 90% of hands going up,

00:23:23.355 --> 00:23:25.035
and that could be across audiences.

00:23:26.340 --> 00:23:29.664
Then when I was back in the UK
again, if you are at biotech events,

00:23:29.724 --> 00:23:31.494
you will get 80 to 90% of hands.

00:23:31.494 --> 00:23:34.760
But this was a more politically
focused event that we were at, and

00:23:34.760 --> 00:23:37.730
maybe it was only 50% of hands that
went up when I asked this question.

00:23:38.240 --> 00:23:40.850
And actually I think that's, a
bit of a reflection on me and

00:23:40.850 --> 00:23:42.140
being in a bubble of the biotech.

00:23:42.140 --> 00:23:45.740
So I had to take a step back and go,
okay, I've been in a bubble here more

00:23:45.740 --> 00:23:50.540
recently, we've got to look at that
perhaps society isn't where we are all at.

00:23:52.235 --> 00:23:55.235
And so we started getting into a little
bit more detail, and it was around

00:23:55.235 --> 00:23:59.000
this well, why can't we eat less and
move more, which is what we were all

00:23:59.000 --> 00:24:01.160
taught at schools sort of 20 years ago.

00:24:01.670 --> 00:24:05.560
Our obesity rates have tripled since the
nineties, and so it just doesn't work.

00:24:05.590 --> 00:24:10.060
And so that's one of the things that got
me so excited when we founded OMP, was

00:24:10.060 --> 00:24:11.860
that we were doing something different.

00:24:11.860 --> 00:24:14.965
We were taking a problem that
kept on being, you know, hit

00:24:14.965 --> 00:24:17.725
with the same stick and we kept
expecting a different solution.

00:24:17.725 --> 00:24:20.725
So for instance, just to put this
in perspective for your listeners,

00:24:21.055 --> 00:24:25.855
John Major was the first prime
minister to put in policy around diet

00:24:25.855 --> 00:24:27.145
and exercise and obesity targets.

00:24:27.415 --> 00:24:30.865
He actually put targets in for
reducing the obesity levels in 1992.

00:24:31.144 --> 00:24:38.934
Since 1992, we've had 689 policies on
diet, exercise, and education, and as I

00:24:38.934 --> 00:24:40.914
just said, our obesity rates have tripled.

00:24:41.514 --> 00:24:46.138
And whilst on an individual level, of
course, it is possible to diet, exercise.

00:24:46.228 --> 00:24:48.988
It just doesn't work on a society scale.

00:24:49.318 --> 00:24:54.013
In fact, if you look at the literature,
it fails 90% over 90% of the time that

00:24:54.013 --> 00:24:57.493
weight will come back on, and quite
often, you know, a little bit more each

00:24:57.493 --> 00:25:00.643
time you go on a diet, you put it on a
little bit more, a little bit more weight.

00:25:01.153 --> 00:25:05.473
And so given the implications of
carrying excessive weight, you know,

00:25:05.473 --> 00:25:11.023
cancer, cardiovascular disease, type two
diabetes, osteoarthritis, infertility.

00:25:11.713 --> 00:25:17.233
We have got to look at this as a disease
and we have to treat it as a disease.

00:25:17.233 --> 00:25:20.383
We're treating all of its essentially
comorbidities as a disease.

00:25:20.383 --> 00:25:23.683
Why don't we actually treat the
underlying excessive weight?

00:25:24.113 --> 00:25:25.243
We have a lot of work to do.

00:25:25.243 --> 00:25:26.893
There is still a lot of stigma.

00:25:27.274 --> 00:25:30.364
Lily and Novo have done an
absolutely fantastic job on that

00:25:30.364 --> 00:25:31.684
and are driving that forward.

00:25:32.194 --> 00:25:35.314
And when we look at the US I would
say they are much more, they're

00:25:35.314 --> 00:25:37.864
much further ahead in their way of
understanding and their thinking,

00:25:37.864 --> 00:25:41.974
and you can see that by some of the
sort of high profile individuals that

00:25:41.974 --> 00:25:45.854
are taking these drugs and saying,
look this has transformed my life.

00:25:46.154 --> 00:25:47.954
I'm suddenly in control of what I can eat.

00:25:47.984 --> 00:25:49.034
I can move more.

00:25:49.034 --> 00:25:50.564
I feel healthier.

00:25:50.924 --> 00:25:52.094
Everybody deserves that.

00:25:52.304 --> 00:25:54.559
Absolutely everybody, not just
the people that can afford it.

00:25:55.254 --> 00:25:56.214
I couldn't agree more.

00:25:56.264 --> 00:25:57.524
I've got a question for you.

00:25:57.734 --> 00:26:02.204
Is there an understanding of why we
put on more weight after Dieting.

00:26:02.339 --> 00:26:05.159
So there is, I'd have to dig
the paper out, but essentially

00:26:05.159 --> 00:26:07.859
there was a very interesting
study done quite a long time ago.

00:26:08.509 --> 00:26:12.481
They took individuals living with
obesity and they asked them to go

00:26:12.481 --> 00:26:15.031
on a starvation diet for 12 weeks.

00:26:15.061 --> 00:26:18.001
So essentially they wanted them
to reduce their weight by 10%

00:26:18.031 --> 00:26:19.381
within that 12 week period.

00:26:19.931 --> 00:26:22.841
At the beginning, before they went from
the diet, they took all of their gut

00:26:22.841 --> 00:26:28.041
hormones, which look at hunger and satiety
really broadly speaking and fullness.

00:26:28.521 --> 00:26:31.761
And then they got to go on this
diet and then the individuals who'd

00:26:31.761 --> 00:26:35.211
managed to lose 10% of their weight,
they took those gut hormones again.

00:26:35.301 --> 00:26:38.871
And as you would a hundred percent
expect the individuals who had lost

00:26:38.871 --> 00:26:40.596
all of that weight were starving.

00:26:40.596 --> 00:26:44.766
If you looked at their biomarkers for
hunger, they were elevated, very elevated.

00:26:44.951 --> 00:26:46.301
And then they said, okay,
well that makes sense.

00:26:46.301 --> 00:26:48.011
You've just been on a starvation diet.

00:26:48.251 --> 00:26:50.591
Your body's telling you
to go out and seek food.

00:26:51.161 --> 00:26:54.401
What about now if you say, just go
about your life, just go back and

00:26:54.401 --> 00:26:57.761
eat what you were eating before, no
diet and come back in a year's time.

00:26:57.761 --> 00:26:58.871
So 52 weeks time.

00:26:59.261 --> 00:27:04.061
And they retook those biomarkers again
and they were still elevated from the very

00:27:04.061 --> 00:27:06.311
original baseline bloods that they did.

00:27:06.731 --> 00:27:12.056
And the theory behind this is
essentially, we for hundreds of

00:27:12.056 --> 00:27:16.616
thousands, millions of years, have
needed to survive through famine and

00:27:17.156 --> 00:27:18.836
more famine than feast, let's face it.

00:27:19.196 --> 00:27:21.836
And so we became very, very good at
saying, well, if we've just had a

00:27:21.836 --> 00:27:25.616
famine, let's put on a little bit
more weight to prepare us for the

00:27:25.616 --> 00:27:28.676
next famine that's going to come
and those people would survive.

00:27:28.676 --> 00:27:29.546
They would reproduce.

00:27:29.546 --> 00:27:32.006
They would survive longer, they'd
have more children, et cetera, and

00:27:32.006 --> 00:27:33.566
they'd obviously pass on those genes.

00:27:33.859 --> 00:27:37.999
We've potentially preselected ourselves in
order to do that cause it was only maybe

00:27:37.999 --> 00:27:42.229
a hundred years ago, 150 years ago, that
food really started to become abundant,

00:27:42.529 --> 00:27:46.229
and really in the last 50 years, very
abundant that we see now with the sort

00:27:46.229 --> 00:27:47.969
of fast food and ultraprocessed food.

00:27:48.269 --> 00:27:51.759
So we now live in an
obesogenic environment.

00:27:51.759 --> 00:27:53.529
Whereas we didn't before.

00:27:53.979 --> 00:27:55.749
And so I think it's very easy
for people to say, well, we

00:27:55.749 --> 00:27:57.099
never used to be overweight.

00:27:57.189 --> 00:27:58.959
How can it possibly be the genetics?

00:27:59.109 --> 00:28:01.244
We didn't have the
environment you need both.

00:28:01.244 --> 00:28:04.214
We had the propensity there but
not the environment, and now we

00:28:04.214 --> 00:28:05.534
have the environment as well.

00:28:05.774 --> 00:28:08.714
And so we have to treat this
very holistically and that

00:28:08.714 --> 00:28:10.364
includes treating this medically.

00:28:10.759 --> 00:28:11.989
That's absolutely fascinating.

00:28:11.989 --> 00:28:15.769
Thank you for explaining that because I
think that's really not well understood.

00:28:16.279 --> 00:28:19.789
It's really exciting to hear about
what OMP is doing, and I think it

00:28:19.789 --> 00:28:23.547
makes so much sense that even in a
marketplace where these things coming

00:28:23.547 --> 00:28:25.407
to market that are really impactful.

00:28:25.557 --> 00:28:29.547
There's space for alternatives and
so much more, particularly something

00:28:29.547 --> 00:28:33.267
like Sirona that is so much less
invasive with fewer side effects.

00:28:33.657 --> 00:28:38.007
I'd love to know from your perspective, in
an ideal world, what are the next steps?

00:28:38.007 --> 00:28:40.827
How much would you be looking to
raise next to go into your next

00:28:40.827 --> 00:28:44.397
stage of approvals, and what sort
of timeframes are we talking about

00:28:44.397 --> 00:28:48.177
until you could potentially be
on a shelf in our local pharmacy?

00:28:48.348 --> 00:28:51.408
So as I just said, we just received
our IDE approval, which is fantastic.

00:28:51.648 --> 00:28:53.628
Full approval to go
into our pivotal trials.

00:28:53.628 --> 00:28:59.644
So this is a, 350, 400 person trial
for long-term weight loss management.

00:29:00.064 --> 00:29:03.604
So we are currently fundraising in
order to conduct those clinical trials.

00:29:03.717 --> 00:29:04.947
And what's the cost of that?

00:29:05.232 --> 00:29:10.062
So we are looking at around about $12
to $14 million to conduct those trials

00:29:10.062 --> 00:29:15.169
and then overheads, et cetera around the
company, and then also we're very keen to

00:29:15.169 --> 00:29:17.089
do a proof of concept weight maintenance.

00:29:17.089 --> 00:29:20.654
I think this is a ticking time
bomb that we're sitting on here.

00:29:21.107 --> 00:29:24.377
We have about 20 million people in
the US at the moment taking a GLP-1.

00:29:24.677 --> 00:29:27.647
We know that 70% of we've already
said will stop taking those.

00:29:28.097 --> 00:29:33.347
We do desperately need a long-term weight
maintenance solution and given our side

00:29:33.347 --> 00:29:37.727
effect profile and given our cost of
goods, we are just beautifully positioned

00:29:37.787 --> 00:29:39.767
to be the solution for that problem.

00:29:40.492 --> 00:29:43.642
So I really desperately want to
get a proof of concept study up

00:29:43.642 --> 00:29:44.812
and running as quickly as possible.

00:29:44.812 --> 00:29:48.652
In fact, we were speaking to some
fantastic UK based clinicians, so

00:29:48.652 --> 00:29:51.292
we're just putting our team together
for that now and I would love to

00:29:51.292 --> 00:29:53.222
conduct that here across the NHS.

00:29:53.222 --> 00:29:56.042
I think we are such a good
ecosystem to be doing those sort

00:29:56.042 --> 00:29:58.562
of phase two, early phase trials.

00:29:59.042 --> 00:30:02.342
So we'd be looking to raise, that
would be about a $7 million raise.

00:30:02.342 --> 00:30:06.512
So really we are looking to raise
somewhere between $30 and $40 million

00:30:06.512 --> 00:30:09.639
for that raise, although, we can pick
and choose which parts that we do.

00:30:09.639 --> 00:30:14.109
So when I'm speaking to investors, like
anything, some parts resonate really

00:30:14.109 --> 00:30:17.769
well, and a lot of people are very excited
about that weight maintenance piece that

00:30:17.769 --> 00:30:21.879
we're talking about because it just fits
really nicely into that sort of weight

00:30:21.879 --> 00:30:24.069
loss journey that entire lifecycle.

00:30:24.719 --> 00:30:27.439
So currently we are raising
for that at the moment across

00:30:27.439 --> 00:30:29.508
Europe and the US predominantly.

00:30:29.508 --> 00:30:32.058
Although actually as we spoke a little
bit earlier, we're starting to look in

00:30:32.058 --> 00:30:35.467
the Middle East because obesity is a
problem that affects people across the

00:30:35.467 --> 00:30:37.117
world, including in the Middle East.

00:30:37.167 --> 00:30:38.727
So as we said, we're just
getting going with this.

00:30:38.817 --> 00:30:42.357
It has been a bit slow, as you
can imagine, through this period.

00:30:42.357 --> 00:30:45.477
But actually I do think
it's starting to pick up.

00:30:45.867 --> 00:30:50.187
So not only are we speaking to your
more traditional BioTech investors,

00:30:50.397 --> 00:30:54.117
we're also starting to get a lot
of interest from more sort of

00:30:54.117 --> 00:30:58.227
wellness consumer base investors
who can see this gap in the market.

00:30:58.527 --> 00:31:02.892
Who can see that we're coming at this
with a very, very different treatment

00:31:02.892 --> 00:31:04.692
option and solution for individuals.

00:31:04.932 --> 00:31:07.662
And our regulatory strategy is
very different, so we don't have

00:31:07.662 --> 00:31:10.402
to have those trials that the
pharma companies have to have.

00:31:10.402 --> 00:31:13.732
We are regulated as a class two
device in the US and we just have

00:31:13.732 --> 00:31:17.512
that one trial left to do, which
is that sort of 350 person trial.

00:31:18.085 --> 00:31:21.235
So ideally, we'll have that
closed out by the end of the year.

00:31:21.235 --> 00:31:23.065
Get into our first patient this year.

00:31:23.305 --> 00:31:26.935
As I said, we're all ready to go really
on that front, which means that'll

00:31:26.935 --> 00:31:28.945
be around about an 18 month trial.

00:31:29.015 --> 00:31:31.085
It's a nine month
treatment plus recruitment.

00:31:31.355 --> 00:31:34.595
So we would look to be on the
market by 2028, early 2028, we'd

00:31:34.595 --> 00:31:35.997
be looking to be on the market.

00:31:36.419 --> 00:31:39.179
So you're talking there about the
FDA approval side of things, but you

00:31:39.179 --> 00:31:42.149
also mentioned the wellness industry.

00:31:42.539 --> 00:31:44.549
Are the route to market different lengths?

00:31:44.669 --> 00:31:48.089
How quickly might you be
able to, if you weren't being

00:31:48.089 --> 00:31:51.004
prescribed, get onto the shelves?

00:31:51.049 --> 00:31:52.009
Yeah, absolutely.

00:31:52.009 --> 00:31:55.821
So, in the US we do have this
strategy in place that we really

00:31:55.821 --> 00:31:57.111
have to go through with the FDA.

00:31:57.381 --> 00:32:01.344
Europe is a slightly different environment
with the regulated notified bodies

00:32:01.344 --> 00:32:05.454
here and actually our competitors
have managed to get their CE marks

00:32:05.454 --> 00:32:08.244
with about the same amount of data we
already have from the clinical trials

00:32:08.244 --> 00:32:09.774
we've already done here in the UK.

00:32:10.044 --> 00:32:13.194
So we will be submitting all of our
preclinical and clinical data in

00:32:13.254 --> 00:32:16.344
order to get that CE mark and we'll
be looking to submit that this year.

00:32:16.344 --> 00:32:19.404
So actually in Europe we may
well be able to hit the market

00:32:19.404 --> 00:32:21.354
sort of back into 26, early 27.

00:32:21.564 --> 00:32:22.764
That's super exciting.

00:32:23.086 --> 00:32:24.286
I wish you all the best with it.

00:32:24.736 --> 00:32:27.599
I'm really excited to see how it
develops, and thank you for coming

00:32:27.679 --> 00:32:28.459
Thank you very much.

00:32:28.464 --> 00:32:28.954
It's been great.

00:32:29.397 --> 00:32:32.347
Thanks for listening to this
episode of Oxford+, presented

00:32:32.367 --> 00:32:33.587
by me, Susannah de Jager.

00:32:33.867 --> 00:32:38.067
If you want to stay up to date with all
things Oxford+, please visit our website,

00:32:38.117 --> 00:32:42.837
oxfordplus.co.uk and sign up for our
newsletter so you never miss an update.

00:32:43.317 --> 00:32:46.617
Oxford+ was made in partnership
with Mishcon de Reya and is produced

00:32:46.617 --> 00:32:48.327
and edited by Story Ninety-Four.